Avicanna Publicizes USPTO Issuance of Patent SEDDS Know-how

TORONTO, June 19, 2024 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Firm”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical firm centered on the event, manufacturing, and commercialization of plant-derived cannabinoid-based merchandise, is happy to announce the USA Patent and Trademark Workplace (“USPTO”) issuance of the Patent masking Avicanna’s SEDDS oral cannabinoid compositions and strategies for treating neuropathic ache.

“We’re delighted to announce the USPTO’s issuance of the Patent masking our SEDDS drug supply expertise. Analysis, growth, and analysis of the potential position of cannabinoids in superior drug supply programs for therapeutic profit have been on the core of the Firm’s mission since inception. We’re appreciative of the work carried out by our scientists which have introduced us to this milestone, and we’re excited concerning the prospects of additional scientific purposes for cannabinoid therapies in neuropathic ache and dealing intently with healthcare suppliers to assist sufferers in want,” acknowledged Aras Azadian, CEO.

Concerning the SEDDS Know-how

As a result of extremely lipophilic nature and poor water-solubility of cannabinoids, the formulations at the moment out there within the Canadian market have been usually described as having poor absorption and excessive variability of onset. SEDDS oral supply programs provide a route for non-invasive and non-inhalation administration of cannabinoids.^1-4 

Avicanna’s SEDDS expertise demonstrated shelf-life stability with greater than 90% of the whole cannabinoid(s) remaining after 6 months in accelerated situations. CBD and THC dissolution profiles have been additionally examined in biorelevant media which mimic human intestinal fluid and demonstrated greater than 90% dispersion inside one hour with continued stabilization of the emulsion.

About Avicanna Inc. 

Avicanna is a commercial-stage worldwide biopharmaceutical firm centered on the development and commercialization of cannabinoid-based merchandise and formulations for the worldwide medical and pharmaceutical market segments. Avicanna has a longtime scientific platform together with R&D and scientific growth resulting in the commercialization of greater than thirty proprietary, evidence-based completed merchandise and supporting 4 business stage enterprise pillars.

Medical Hashish formulary (RHO Phyto™): The formulary gives a various vary of proprietary merchandise together with oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids, supported by ongoing affected person and medical group schooling. RHO Phyto is a longtime main medical model in Canada at the moment out there nationwide to sufferers throughout a number of medical channels and continues to increase into new worldwide markets.

Medical hashish care platform (MyMedi.ca): MyMedi.ca is a medical hashish care platform shaped with the purpose to higher serve medical hashish sufferers’ wants and improve the affected person journey. MyMedi.ca is operated by Northern Inexperienced Canada Inc. and contains a numerous portfolio of merchandise and bilingual pharmacist-led affected person assist packages. MyMedi.ca additionally supplies specialty providers to distinct affected person teams corresponding to veterans and collaborates with private and non-private payers for adjudication and reimbursement. MyMedi.ca supplies instructional sources to the medical group to facilitate the incorporation of medical hashish into well being care regimens.

Pharmaceutical merchandise (Trunerox™) and pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world proof, Avicanna has developed a pipeline of proprietary, indication-specific pharmaceutical merchandise which can be in numerous levels of scientific growth. These cannabinoid-based drug candidates purpose to handle unmet medical wants in dermatology, persistent ache, and numerous neurological problems. Avicanna’s first indication-specific pharmaceutical drug, Trunerox™, was accepted Q1 2024 by the Well being Authority of Colombia INVIMA as an adjuvant therapy for seizures related to Lennox-Gastaut Syndrome and Dravet Syndrome in Colombia. Trunerox™ has not been accepted as a drug in Canada by Well being Canada.

Energetic pharmaceutical elements (Aureus Santa Marta™): Energetic pharmaceutical elements are equipped by the Firm’s majority owned subsidiary Santa Marta Golden Hemp SAS which is a commercial-stage enterprise devoted to offering a numerous kinds high-quality CBD, THC and CBG to the Firm’s worldwide companions to be used within the growth and manufacturing of meals, cosmetics, medical, and pharmaceutical merchandise. The enterprise unit additionally kinds a part of the Firm’s provide chain and is a supply of dependable enter merchandise for its client retail, medical hashish, and pharmaceutical merchandise globally.

References:

¹ Maji, et al., Stable self emulsifying drug supply system: Superior mode for oral supply of hydrophobic cargos. Journal of Managed Launch, 337, 2021;646-660.

² Salawi A. Self-emulsifying drug supply programs: a novel strategy to ship medicine. Drug Deliv. 2022 Dec;29(1):1811-1823.

³ Khaled, A.; Ayat, A. A.; Mahmoud, E.-B., Self-Emulsifying Drug Supply Programs: Straightforward to Put together Multifunctional Vectors for Environment friendly Oral Supply. In Present and Future Elements of Nanomedicine, Islam Ahmed Hamed, Ok., Ed. IntechOpen: Rijeka, 2019; p Ch. 4

⁴ Pathak, Ashish Kumar et al. “Current advances in self emulsifying drug supply system – A evaluate.” Drug Invention At this time (2010): 123-129.

SOURCE Avicanna Inc. 

Keep Related 

For extra details about Avicanna, go to our web site, contact Ivana Maric by e-mail at [email protected] or observe us on social media on LinkedIn, Twitter, Fb, or Instagram. 

The Firm posts updates by means of movies from the Firm YouTube channel. 

Cautionary Be aware Relating to Ahead-Wanting Info and Statements 

This information launch comprises “forward-looking data” inside the which means of relevant securities legal guidelines. Ahead-looking data contained on this information launch could also be recognized utilizing phrases corresponding to, “could”, “would”, “may”, “will”, “possible”, “anticipate”, “anticipate”, “consider”, “intend”, “plan”, “forecast”, “undertaking”, “estimate”, “outlook” and different related expressions. Though the Firm believes that the expectations and assumptions on which such ahead wanting data relies are cheap, undue reliance shouldn’t be positioned on the forward-looking data as a result of the Firm may give no assurance that they may show to be appropriate. Precise outcomes and developments could differ materially from these contemplated by these statements. Ahead-looking data is topic to quite a lot of dangers and uncertainties that might trigger precise occasions or outcomes to vary materially from these projected within the forward-looking data. Such dangers and uncertainties embrace however are usually not restricted to present and future market situations, together with the market value of the widespread shares of the Firm, and the danger components set out within the Firm’s annual data kind dated April 1, 2024 filed with the Canadian securities regulators and out there underneath the Firm’s profile on SEDAR at www.sedar.com. The statements on this information launch are made as of the date of this launch. The Firm disclaims any intent or obligation to replace any forward-looking data, whether or not on account of new data, future occasions or outcomes or in any other case, aside from as required by relevant securities legal guidelines.